Press Release

PhRMA Supports Customs Facilitation and Trade Enforcement

PhRMA August 7, 2009

Washington, D.C. (August 7, 2009) — The Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Ken Johnson issued the following statement regarding PhRMA support for Senate introduction of the Customs Facilitation and Trade Enforcement Reauthorization Act of 2009 (CFTERA):

“Strong intellectual property (IP) protections play a critical role in spurring research and development of innovative medicines and American patients are the ultimate beneficiaries of new and better treatments and cures. We applaud the efforts of Senate Finance Committee Chairman Max Baucus (D-MT) and Ranking Member Charles Grassley (R-IA) to strengthen IP rights enforcement, improve trade facilitation, modernize the customs service and ensure import safety.

“The CFTERA will significantly improve the ability of the U.S. Customs and Border Protection Agency (CBP) and U.S. Immigration and Customs Enforcement Agency (ICE) to do their jobs. In particular, the legislation strengthens key IP enforcement and import safety efforts at the critical agencies and also improves interagency consultation and cooperation.

“This timely legislation is necessary to better help detect and target cargo that may violate U.S. customs and trade laws. But more importantly, the CFTERA will help safeguard Americans’ health and safety by equipping these key agencies to better respond to imports that put American patients at a higher risk by failing to meet U.S. health and safety requirements.”

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $50.3 billion in 2008 in discovering and developing new medicines. Industry-wide research and investment reached a record $65.2 billion in 2008.

PhRMA Internet Address:

For information on how innovative medicines save lives, visit:

For information on the Partnership for Prescription Assistance, visit:

For more information on public health emergencies, visit

For information on the danger of imported drugs, visit: